HomeAI · summaries
Storia in 2 fonti
After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug
Merging with NextCure, Avere Therapeutics is based on a clinical-stage oral IL-23 receptor antagonist licensed from China's Hansoh Pharmaceutical for $120 million upfront.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
- ·
endpoints.news
After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug
Merging with NextCure, Avere Therapeutics is based on a clinical-stage oral IL-23 receptor antagonist licensed from China's Hansoh Pharmaceutical for $120 million upfront.